Stocks · News reference
Bruker Affirms FY2026 Adj EPS Guidance of $2.10-$2.15 vs $2.12 Est; Lowers FY2026 Sales Guidance from $3.570B-$3.600B to $3.540B-$3.570B vs $3.589B Est
Bruker (NASDAQ:BRKR) affirms FY2026 Adj EPS guidance from $2.10-$2.15 to $2.10-$2.15 vs $2.12 analyst estimate. Lowers FY2026 sales outlook from $3.570 billion-$3.600 billion to $3.540 billion-$3.570 billion vs $3.589
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 4, 2026, 11:05 AM
- Checked
- Aug 4, 2026, 11:05 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Bruker shares are trading higher after the company announced a majority investment in MIMETAS to expand its post‑genomic solutions and advance drug discovery through microphysiological systems.
Read original at benzingaBruker Announces Majority Investment In Organ-On-A-Chip Developer MIMETAS, Expanding Into Microphysiological Systems For Drug Discovery; Terms Not Disclosed
Read original at benzingaCitigroup Maintains Neutral on Bruker, Lowers Price Target to $53
Citigroup analyst Brendan Digan maintains Bruker (NASDAQ:BRKR) with a Neutral and lowers the price target from $60 to $53.
Read original at benzinga